Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 285-291 , April 2008

Androgen deprivation therapy for precancerous lesions of the prostate

  • David Hull, MD (Staff Pathologist)
    • ,
  • David G. Bostwick, MD, MBA (CEO and Medical Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 804 967 9225; Fax: +1 804 545 1690.

References 

  1. Bostwick DG NR, Qian J, Cheng L. Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention. European Urology. 1999;35(5–6):492–495
  2. Srigley JR. Benign mimickers of prostatic adenocarcinoma. Modern Pathology. 2004;17:328–348
  3. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 2000;56:828–832
  4. Postma R, Schroder FH, van der Kwast TH. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology. 2005;65:745–749
  5. McNeal JE. Morphogenesis of prostatic carcinoma. Cancer. 1965;18:1659–1666
  6. Prostatic intraepithelial neoplasia: significance and correlation with prostate-specific antigen and transrectal ultrasound. Proceedings of a workshop of the National Prostate Cancer Detection Project. March 13, 1989, Bethesda, Maryland. Urology. 1989;34:2–69
  7. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Human Pathology. 1986;17:64–71
  8. Epstein JI, Grignon DJ, Humphrey PA, et al. Inter-observer reproducibility in the diagnosis of prostatic intraepithelial neoplasia. American Journal of Surgical Pathology. 1995;19:873–886
  9. Bostwick DG, Amin MB, Dundore P, et al. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Human Pathology. 1993;24:298–310
  10. Sakr WA, Billis A, Ekman P, et al. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scandinavian Journal of Urology and Nephrology Supplementum. 2000;11–18
  11. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (Athens, Greece). 1994;8:439–443
  12. Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. European Urology. 1996;30:138–144
  13. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. The Journal of Urology. 1993;150:379–385
  14. Rubin MA, Zhou M, Dhanasekaran SM, et al., Chinnaiyan AM Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. The Journal of the American Medical Association. 2002;287:1662–1670
  15. Emmert-Buck MR, Vocke CD, Pozzatti RO, et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Research. 1995;55:2959–2962
  16. Qian J, Bostwick DG, Takahashi S, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Research. 1995;55:5408–5414
  17. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research. 1941;1:293–297
  18. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proceedings of the National Academy of Sciences of the United States of America. 1982;79:1658–1662
  19. Waxman J, Man A, Hendry WF, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. British Medical Journal (Clinical Research Ed.). 1985;291:1387–1388
  20. Loumaye E, Catt KJ. Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells. Science. 1982;215:983–985
  21. Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. The Urologic Clinics of North America. 1991;18:111–122
  22. Labrie F, Belanger A, Simard J, et al. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer. 1993;71:1059–1067
  23. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry. 1985;23:833–841
  24. Normington K, Russell DW. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. The Journal of Biological Chemistry. 1992;267:19548–19554
  25. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. The Journal of Clinical Investigation. 1993;92:903–910
  26. Thomas LN LC, Gupta R, Norman RW, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. The Prostate. 2005;63(3):231–239
  27. Raghow S HM, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Research. 2002;62(5):1370–1376
  28. Montironi R, Magi-Galluzzi C, Muzzonigro G, et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Journal of Clinical Pathology. 1994;47:906–913
  29. Bullock MJ, Srigley JR, Klotz LH, et al. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. American Journal of Surgical Pathology. 2002;26:1400–1413
  30. van der Kwast TH, Labrie F, Tetu B. Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Human Pathology. 1999;30:1503–1507
  31. Ferguson J, Zincke H, Ellison E, et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology. 1994;44:91–95
  32. Vailancourt L, Ttu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. American Journal of Surgical Pathology. 1996;20:86–93
  33. Thompson IM, Coltman CA, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. The Prostate. 1997;33:217–221
  34. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine. 2003;349:215–224
  35. Thompson IM, Lucia MS, Redman MW, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. The Journal of Urology. 2007;178:107–109[discussion: 110]
  36. Andriole G BD, Brawley O, Gomella L, et al. REDUCE Study Group Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. The Journal of Urology. 2004;172(4 Pt 1):1314–1317
  37. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. The Journal of Urology. 2004;172:915–919
  38. Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology. 1999;53:696–700
  39. Civantos F WR, Pinto JE, Korman JH, et al. Finasteride effect on prostate cancer: a comparative clincopathologic study of radical prostatectomies. Journal of Urologic Pathology. 1997;6:1–8
  40. Montironi R PR, Diamanti L, Hamilton PW, et al. Evaluation of prostatic intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor (finasteride). A methodologic approach. Analytical and Quantitative Cytology and Histology. 1996;18(6):461–470
  41. Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005;65:76–82
  42. Price D, Stein B, Sieber P, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. The Journal of Urology. 2006;176(3):965–970

PII: S1521-690X(08)00007-9

doi: 10.1016/j.beem.2008.01.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 285-291 , April 2008

Article Tools

* Image Usage & Resolution